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Many botanical products are used widely in the United
States. Depending on its labeling and intended use, a bota-
nical product can be a food, a dietary supplement, and/or
a drug. If a botanical product is intended for use in diag-
nosing, mitigating, treating, or curing disease, it is a drug
under the Food, Drug, and Cosmetic Act and is subject to
applicable drug regulations. The CDER Guidance on Bota-
nical Drug Products defines the term “Botanical” as a fin-
ished, labeled product that contains drug substance from
plant origins, which may include plants or plant parts,
algae, macroscopic fungi, and combinations thereof. The
term does not include highly purified substances or che-
mically modified substances derived from botanical
sources. This presentation provides an overview of the
Chemistry, Manufacturing, and Controls (CMC) informa-
tion recommended to support the clinical studies of a
botanical drug product under an investigational new drug
application (IND) in the United States. Veregen (sinecata-
chins) ointment1 was the first botanical drug product
approved by the FDA since publication of the Botanical
Guidance (2004)2. While the Guidance gave a general
pathway for IND submissions, it was silent on the require-
ments for NDA approval. A “CDER Botanical Guidance
rewrite Working Group” has been established and the
work is in progress to consolidate the FDA’s current scien-
tific and regulatory thinking in the future Botanical
Guidance.
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